Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer's disease (REFLECT-4).
rosiglitazone
AVA102675
NCT00490568
Alzheimer's Disease
Phase 3
 
This is a follow-up study to AVA102672.
May 2013

Powered by ideaPoint, Inc.